{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:36:04Z","timestamp":1790246164909,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/leu.2017.212","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T09:59:48Z","timestamp":1499248788000},"page":"391-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma"],"prefix":"10.1038","volume":"32","author":[{"given":"A","family":"Besse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S C","family":"Stolze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G J","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H S","family":"Overkleeft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"BFleu2017212_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S . Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2016; 91: 101\u2013119.","journal-title":"Mayo Clin Proc"},{"key":"BFleu2017212_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2050-7771-1-13","volume":"1","author":"S Lu","year":"2013","unstructured":"Lu S, Wang J . The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res 2013; 1: 13.","journal-title":"Biomark Res"},{"key":"BFleu2017212_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S . Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med 2014; 18: 947\u2013961.","journal-title":"J Cell Mol Med"},{"key":"BFleu2017212_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27\u201338.","journal-title":"Lancet Oncol"},{"key":"BFleu2017212_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","volume":"124","author":"S Bringhen","year":"2014","unstructured":"Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014; 124: 63\u201369.","journal-title":"Blood"},{"key":"BFleu2017212_CR6","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","volume":"125","author":"AK Nooka","year":"2015","unstructured":"Nooka AK, Kastritis E, Dimopoulos MA, Lonial S . Treatment options for relapsed and refractory multiple myeloma. Blood 2015; 125: 3085\u20133099.","journal-title":"Blood"},{"key":"BFleu2017212_CR7","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691\u20134695.","journal-title":"Blood"},{"key":"BFleu2017212_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149\u2013157.","journal-title":"Leukemia"},{"key":"BFleu2017212_CR9","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","volume":"127","author":"RC Baz","year":"2016","unstructured":"Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 2016; 127: 2561\u20132568.","journal-title":"Blood"},{"key":"BFleu2017212_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/bjh.13067","volume":"167","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves WI, Morice WG, Rajkumar V, Gupta V, Timm MM, Dispenzieri A et al. Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol 2014; 167: 500\u2013505.","journal-title":"Br J Haematol"},{"key":"BFleu2017212_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3109\/10428194.2011.627481","volume":"53","author":"V Peceliunas","year":"2012","unstructured":"Peceliunas V, Janiulioniene A, Matuzeviciene R, Zvirblis T, Griskevicius L . Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma 2012; 53: 641\u2013647.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017212_CR12","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","volume":"120","author":"NW van de Donk","year":"2012","unstructured":"van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG . How I treat plasma cell leukemia. Blood 2012; 120: 2376\u20132389.","journal-title":"Blood"},{"key":"BFleu2017212_CR13","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1126\/science.1209038","volume":"334","author":"P Walter","year":"2011","unstructured":"Walter P, Ron D . The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011; 334: 1081\u20131086.","journal-title":"Science"},{"key":"BFleu2017212_CR14","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr., Lee KP, Boise LH . Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907\u20134916.","journal-title":"Blood"},{"key":"BFleu2017212_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013; 24: 289\u2013304.","journal-title":"Cancer Cell"},{"key":"BFleu2017212_CR16","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/leu.2016.102","volume":"30","author":"GP Soriano","year":"2016","unstructured":"Soriano GP, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N et al. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia 2016; 30: 2198\u20132207.","journal-title":"Leukemia"},{"key":"BFleu2017212_CR17","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2009.123","volume":"23","author":"D Gutman","year":"2009","unstructured":"Gutman D, Morales AA, Boise LH . Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. Leukemia 2009; 23: 2181\u20132183.","journal-title":"Leukemia"},{"key":"BFleu2017212_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ajh.23387","volume":"88","author":"TS Hawley","year":"2013","unstructured":"Hawley TS, Riz I, Yang W, Wakabayashi Y, Depalma L, Chang YT et al. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol 2013; 88: 265\u2013272.","journal-title":"Am J Hematol"},{"key":"BFleu2017212_CR19","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383\u20136391.","journal-title":"Cancer Res"},{"key":"BFleu2017212_CR20","first-page":"1","volume":"9","author":"MF Ullah","year":"2008","unstructured":"Ullah MF . Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev 2008; 9: 1\u20136.","journal-title":"Asian Pac J Cancer Prev"},{"key":"BFleu2017212_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd4461","volume":"14","author":"SK Nigam","year":"2015","unstructured":"Nigam SK . What do drug transporters really do? Nat Rev Drug Discov 2015; 14: 29\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu2017212_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3109\/10428199509056847","volume":"17","author":"LM Pilarski","year":"1995","unstructured":"Pilarski LM, Belch AR . Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. Leuk Lymphoma 1995; 17: 367\u2013374.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017212_CR23","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood.V90.9.3751","volume":"90","author":"LM Pilarski","year":"1997","unstructured":"Pilarski LM, Szczepek AJ, Belch AR . Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood 1997; 90: 3751\u20133759.","journal-title":"Blood"},{"key":"BFleu2017212_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1385\/MO:19:2:87","volume":"19","author":"H Schwarzenbach","year":"2002","unstructured":"Schwarzenbach H . Expression of MDR1\/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002; 19: 87\u2013104.","journal-title":"Med Oncol"},{"key":"BFleu2017212_CR25","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ajh.20656","volume":"81","author":"Y Nakagawa","year":"2006","unstructured":"Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006; 81: 824\u2013831.","journal-title":"Am J Hematol"},{"key":"BFleu2017212_CR26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1593\/neo.10228","volume":"12","author":"S Meister","year":"2010","unstructured":"Meister S, Frey B, Lang VR, Gaipl US, Schett G, Schlotzer-Schrehardt U et al. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. Neoplasia 2010; 12: 550\u2013561.","journal-title":"Neoplasia"},{"key":"BFleu2017212_CR27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.V78.1.44.44","volume":"78","author":"SE Salmon","year":"1991","unstructured":"Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44\u201350.","journal-title":"Blood"},{"key":"BFleu2017212_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbrc.2007.07.049","volume":"361","author":"H Rumpold","year":"2007","unstructured":"Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D . Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 2007; 361: 549\u2013554.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu2017212_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1476-5381.2011.01618.x","volume":"165","author":"K Mandery","year":"2012","unstructured":"Mandery K, Glaeser H, Fromm MF . Interaction of innovative small molecule drugs used for cancer therapy with drug transporters. Br J Pharmacol 2012; 165: 345\u2013362.","journal-title":"Br J Pharmacol"},{"key":"BFleu2017212_CR30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1146\/annurev.med.53.052901.131947","volume":"53","author":"A Wlodawer","year":"2002","unstructured":"Wlodawer A . Rational approach to AIDS drug design through structural biology. Annu Rev Med 2002; 53: 595\u2013614.","journal-title":"Annu Rev Med"},{"key":"BFleu2017212_CR31","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nrd2336","volume":"6","author":"C Flexner","year":"2007","unstructured":"Flexner C . HIV drug development: the next 25 years. Nat Rev Drug Discov 2007; 6: 959\u2013966.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu2017212_CR32","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-07-0161","volume":"13","author":"JJ Gills","year":"2007","unstructured":"Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13: 5183\u20135194.","journal-title":"Clin Cancer Res"},{"key":"BFleu2017212_CR33","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-16-0024","volume":"22","author":"RE Meyn","year":"2016","unstructured":"Meyn RE, Krishnan S, Skinner HD . Everything old is new again: using nelfinavir to radiosensitize rectal cancer. Clin Cancer Res 2016; 22: 1834\u20131836.","journal-title":"Clin Cancer Res"},{"key":"BFleu2017212_CR34","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1158\/1078-0432.CCR-15-1489","volume":"22","author":"EJ Hill","year":"2016","unstructured":"Hill EJ, Roberts C, Franklin JM, Enescu M, West N, MacGregor TP et al. Clinical trial of oral nelfinavir before and during radiation therapy for advanced rectal cancer. Clin Cancer Res 2016; 22: 1922\u20131931.","journal-title":"Clin Cancer Res"},{"key":"BFleu2017212_CR35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.radonc.2016.03.021","volume":"119","author":"JM Wilson","year":"2016","unstructured":"Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C et al. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol 2016; 119: 306\u2013311.","journal-title":"Radiother Oncol"},{"key":"BFleu2017212_CR36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood.V128.22.487.487","volume":"128","author":"C Driessen","year":"2016","unstructured":"Driessen C, M\u00fcller R, Novak U, Cantoni N, Betticher D, Mach N et al. The HIV protease inhibitor nelfinavir in combination with bortezomib and dexamethasone (NVd) has excellent activity in patients with advanced, proteasome inhibitor-refractory multiple myeloma: a multicenter phase II trial (SAKK 39\/13). Blood 2016; 128: 487.","journal-title":"Blood"},{"key":"BFleu2017212_CR37","first-page":"754","volume":"29","author":"L Huang","year":"2001","unstructured":"Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW . Induction of P-glycoprotein and cytochrome P450 3\u2009A by HIV protease inhibitors. Drug Metab Dispos 2001; 29: 754\u2013760.","journal-title":"Drug Metab Dispos"},{"key":"BFleu2017212_CR38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1248\/bpb.28.316","volume":"28","author":"M Kageyama","year":"2005","unstructured":"Kageyama M, Namiki H, Fukushima H, Ito Y, Shibata N, Takada K . In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol Pharm Bull 2005; 28: 316\u2013322.","journal-title":"Biol Pharm Bull"},{"key":"BFleu2017212_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.biochi.2016.01.014","volume":"124","author":"G Chakravarty","year":"2016","unstructured":"Chakravarty G, Mathur A, Mallade P, Gerlach S, Willis J, Datta A et al. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7\/Dox breast cancer cells. Biochimie 2016; 124: 53\u201364.","journal-title":"Biochimie"},{"key":"BFleu2017212_CR40","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","volume":"99","author":"F Zhan","year":"2002","unstructured":"Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745\u20131757.","journal-title":"Blood"},{"key":"BFleu2017212_CR41","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/leu.2009.8","volume":"23","author":"T Ruckrich","year":"2009","unstructured":"Ruckrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M et al. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 2009; 23: 1098\u20131105.","journal-title":"Leukemia"},{"key":"BFleu2017212_CR42","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1002\/anie.201509092","volume":"55","author":"G de Bruin","year":"2016","unstructured":"de Bruin G, Xin BT, Kraus M, van der Stelt M, van der Marel GA, Kisselev AF et al. A set of activity-based probes to visualize human (immuno)proteasome activities. Angew Chem Int Ed Engl 2016; 55: 4199\u20134203.","journal-title":"Angew Chem Int Ed Engl"},{"key":"BFleu2017212_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1023\/B:BIRE.0000007693.33521.18","volume":"23","author":"LF Marques-Santos","year":"2003","unstructured":"Marques-Santos LF, Oliveira JGP, Maia RC, Rumjanek VM . Mitotracker green is a P-glycoprotein substrate. Bioscience Rep 2003; 23: 199\u2013212.","journal-title":"Bioscience Rep"},{"key":"BFleu2017212_CR44","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1002\/eji.200535364","volume":"35","author":"S Wirths","year":"2005","unstructured":"Wirths S, Lanzavecchia A . ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells. Eur J Immunol 2005; 35: 3433\u20133441.","journal-title":"Eur J Immunol"},{"key":"BFleu2017212_CR45","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nprot.2013.065","volume":"8","author":"N Li","year":"2013","unstructured":"Li N, Kuo CL, Paniagua G, van den Elst H, Verdoes M, Willems LI et al. Relative quantification of proteasome activity by activity-based protein profiling and LC-MS\/MS. Nat Protoc 2013; 8: 1155\u20131168.","journal-title":"Nat Protoc"},{"key":"BFleu2017212_CR46","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F . Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 2014; 11: 783\u2013784.","journal-title":"Nat Methods"},{"key":"BFleu2017212_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014; 343: 84\u201387.","journal-title":"Science"},{"key":"BFleu2017212_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1155\/2013\/204141","volume":"2013","author":"S Kumar","year":"2013","unstructured":"Kumar S, Mukherjee MM, Varela MF . Modulation of bacterial multidrug resistance efflux pumps of the major facilitator superfamily. Int J Bacteriol 2013; 2013: 15.","journal-title":"Int J Bacteriol"},{"key":"BFleu2017212_CR49","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/75406","volume":"18","author":"NP Dantuma","year":"2000","unstructured":"Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG . Short-lived green fluorescent proteins for quantifying ubiquitin\/proteasome-dependent proteolysis in living cells. Nat Biotechnol 2000; 18: 538\u2013543.","journal-title":"Nat Biotechnol"},{"key":"BFleu2017212_CR50","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1172\/JCI22954","volume":"115","author":"JG Weaver","year":"2005","unstructured":"Weaver JG, Tarze A, Moffat TC, Lebras M, Deniaud A, Brenner C et al. Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor. J Clin Invest 2005; 115: 1828\u20131838.","journal-title":"J Clin Invest"},{"key":"BFleu2017212_CR51","doi-asserted-by":"publisher","first-page":"e642","DOI":"10.1371\/journal.pntd.0000642","volume":"4","author":"P Kumar","year":"2010","unstructured":"Kumar P, Lodge R, Trudel N, Ouellet M, Ouellette M, Tremblay MJ . Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes. PLoS Negl Trop Dis 2010; 4: e642.","journal-title":"PLoS Negl Trop Dis"},{"key":"BFleu2017212_CR52","doi-asserted-by":"publisher","first-page":"17197","DOI":"10.1074\/jbc.M310329200","volume":"279","author":"C Batandier","year":"2004","unstructured":"Batandier C, Leverve X, Fontaine E . Opening of the mitochondrial permeability transition pore induces reactive oxygen species production at the level of the respiratory chain complex I. J Biol Chem 2004; 279: 17197\u201317204.","journal-title":"J Biol Chem"},{"key":"BFleu2017212_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1152\/physrev.00013.2006","volume":"87","author":"G Kroemer","year":"2007","unstructured":"Kroemer G, Galluzzi L, Brenner C . Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99\u2013163.","journal-title":"Physiol Rev"},{"key":"BFleu2017212_CR54","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.V74.3.913.913","volume":"74","author":"J Epstein","year":"1989","unstructured":"Epstein J, Xiao HQ, Oba BK . P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913\u2013917.","journal-title":"Blood"},{"key":"BFleu2017212_CR55","first-page":"288","volume":"75","author":"G Carulli","year":"1990","unstructured":"Carulli G, Petrini M, Marini A, Ambrogi F, Ucci G, Riccardi A et al. P-glycoprotein expression in multiple myeloma. Haematologica 1990; 75: 288\u2013290.","journal-title":"Haematologica"},{"key":"BFleu2017212_CR56","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","volume":"106","author":"GS Nowakowski","year":"2005","unstructured":"Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106: 2276\u20132279.","journal-title":"Blood"},{"key":"BFleu2017212_CR57","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2015.135780","volume":"101","author":"C Driessen","year":"2016","unstructured":"Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F et al. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65\/08). Haematologica 2016; 101: 346\u2013355.","journal-title":"Haematologica"},{"key":"BFleu2017212_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3109\/10428194.2014.907890","volume":"56","author":"J Abraham","year":"2015","unstructured":"Abraham J, Salama NN, Azab AK . The role of P-glycoprotein in drug resistance in multiple myeloma. Leuk Lymph 2015; 56: 26\u201333.","journal-title":"Leuk Lymph"},{"key":"BFleu2017212_CR59","doi-asserted-by":"publisher","first-page":"e432","DOI":"10.1038\/bcj.2016.40","volume":"6","author":"N Nikesitch","year":"2016","unstructured":"Nikesitch N, Tao C, Lai K, Killingsworth M, Bae S, Wang M et al. Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response. Blood Cancer J 2016; 6: e432.","journal-title":"Blood Cancer J"},{"key":"BFleu2017212_CR60","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s11095-009-9896-0","volume":"26","author":"P Matsson","year":"2009","unstructured":"Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P . Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 2009; 26: 1816\u20131831.","journal-title":"Pharm Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017212","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:08:29Z","timestamp":1684433309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFleu2017212"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.212","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]},"assertion":[{"value":"16 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}